NovoCure (NVCR) Files $300M Common Stock IPO

NovoCure Limited (Nasdaq: NVCR) filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The proposed maximum offering price is $300 million. The company plans to list on the Nasdaq under the ticker, NVCR.

Underwriters are J.P. Morgan, Deutsche Bank Securities, Evercore ISI, Wells Fargo Securities, JMP Securities, and Wedbush PacGrow.

NovoCure is a commercial-stage oncology company developing a novel, proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on key molecules inside cancer cells, disrupting the basic machinery necessary for normal cell division, leading to cancer cell death. Physicians have typically treated patients with solid tumors using one or a combination of three principal treatment modalities—surgery, radiation and pharmacological therapies. Despite meaningful advancements in each of these modalities, a significant unmet need to improve survival and quality of life remains. We believe we will establish TTFields as a new treatment modality for a variety of solid tumors that increases survival without significantly increasing side effects when used in combination with other cancer treatment modalities.

You May Also Be Interested In

• Tungray Technologies (TRSG) Closes $5M IPO
• Canaan Inc. (CAN) Announces Proposed Share Purchase by Management
• LuxUrban Hotels (LUXH) Files $50M Mixed Shelf